Harvard Bioscience
HBIO
Harvard Bioscience (HBIO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.14
- EPS estimate
- −$0.21
- EPS surprise
- +33.33%
- Revenue surprise
- +5.95%
- Revenue
- $22.7M
- Revenue estimate
- $21.4M
- Reported
- Aug 11, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | −$0.21 | −$0.14 | +33.33% | $22.7M | SEC |
| Q1 2026 | May 12, 2026 | −$0.62 | −$0.33 | +46.77% | $20.8M | SEC |
| Q4 2025 | Mar 12, 2026 | $0.35 | $0.00 | −100.00% | $23.7M | SEC |
| Q3 2025 | Nov 6, 2025 | $0.05 | $0.00 | −100.00% | $20.6M | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.25 | −$0.10 | +60.00% | $20.4M | SEC |
| Q1 2025 | May 12, 2025 | −$0.40 | −$0.10 | +75.00% | $21.8M | SEC |
| Q4 2024 | Mar 12, 2025 | $0.50 | $0.60 | +20.00% | $24.6M | SEC |
| Q3 2024 | Nov 7, 2024 | $0.15 | −$0.20 | −233.33% | $22.0M | SEC |
| Q2 2024 | Aug 8, 2024 | $0.50 | $0.00 | −100.00% | $23.1M | SEC |
| Q1 2024 | May 7, 2024 | $0.37 | $0.20 | −45.46% | $24.5M | SEC |
| Q4 2023 | Mar 7, 2024 | $0.50 | $0.40 | −20.00% | $28.2M | SEC |
| Q3 2023 | Nov 7, 2023 | $0.40 | $0.10 | −75.00% | $25.4M | SEC |
| Q2 2023 | Aug 8, 2023 | $0.60 | $0.40 | −33.33% | $28.8M | SEC |
| Q1 2023 | Apr 25, 2023 | $0.50 | $0.60 | +20.00% | $30.0M | SEC |
| Q4 2022 | Mar 9, 2023 | $0.33 | $0.40 | +20.01% | $28.4M | SEC |
| Q3 2022 | Nov 8, 2022 | $0.67 | −$0.10 | −115.00% | $26.9M | — |
| Q2 2022 | Aug 4, 2022 | $0.60 | $0.50 | −16.67% | $29.2M | — |
| Q1 2022 | May 4, 2022 | $0.45 | $0.40 | −11.11% | $28.8M | — |
| Q4 2021 | Mar 8, 2022 | $1.00 | $0.80 | −20.00% | $33.1M | — |
| Q3 2021 | Nov 3, 2021 | $0.50 | $0.60 | +20.00% | $29.7M | — |
Quarterly revenue
Frequently asked questions
When did Harvard Bioscience (HBIO) last report earnings?
Harvard Bioscience last reported on Aug 11, 2026, covering fiscal Q2 2026.
Did HBIO beat earnings estimates?
Yes. Harvard Bioscience reported EPS of −$0.14 for Q2 2026 against a −$0.21 estimate — a 33.33% beat.
How much revenue did HBIO report last quarter?
Harvard Bioscience reported $22.7M in revenue for Q2 2026, against a consensus estimate of $21.4M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.